{"product_id":"aytubio-bcg-matrix","title":"Aytu Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAytu’s BCG Matrix preview highlights where its core products may sit across Stars, Cash Cows, Dogs, and Question Marks, offering a quick read on growth potential and portfolio risks; the full report expands this into quadrant-level placements, market-share drivers, and prioritized strategic moves. Purchase the complete BCG Matrix for a detailed Word report plus an editable Excel summary that delivers data-backed recommendations, resource allocation guidance, and ready-to-present visuals to help you act with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEXXUA (Gepirone ER) Commercial Launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, EXXUA (gepirone ER) is Aytu’s primary Star after its Q4 2025 U.S. launch, targeting the $22 billion major depressive disorder market; early 2026 forecasts model peak sales of $800M–$1.2B by 2030 under base-case uptake assumptions.\u003c\/p\u003e\n\u003cp\u003eEXXUA is first-in-class selective serotonin 5HT1a receptor agonist and reportedly avoids common SSRI\/SNRI sexual dysfunction; analysts expect 30%+ CAGR in initial five years but note a heavy upfront marketing spend of $80M–$150M for national rollout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric Portfolio Growth Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Pediatric Portfolio, led by Karbinal ER and fluoride-based vitamins, moved into Star status by mid-2025 with revenue growth up to 77% YoY and estimated 2025 sales of ~$48M, driven by a return-to-growth plan that restored payer coverage and expanded sales rep reach from 120 to 220 territories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAytu RxConnect Platform Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe proprietary RxConnect patient-access platform is a Star: it raised Aytu Biopharma’s prescription fulfillment rate to ~92% and cut patient out-of-pocket costs by 28% in 2024, driving a 35% CAGR in Rx volume across core brands.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 RxConnect optimizes brand economics—lowering cost-per-prescription by an estimated $14 and boosting gross-to-net recovery—giving Aytu a clear edge in telehealth and digital pharmacy growth.\u003c\/p\u003e\n\u003cp\u003eOngoing $8–10M annual investments are needed to scale RxConnect as Aytu integrates new products like EXXUA into commercial ops and target an additional 50% prescription volume lift over 2026–2027.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdzenys XR-ODT Market Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdzenys XR-ODT retained leadership in ADHD after 2024 stimulant shortages, with Aytu reporting double-digit sequential revenue growth through 2025 and a reset baseline that recovered market share versus peers.\u003c\/p\u003e\n\u003cp\u003eOrally disintegrating tablet formulation drove uptake and higher adherence; product still needs sustained promotional spend to defend share against generics and branded competitors in a crowded market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDouble-digit sequential revenue growth in 2025\u003c\/li\u003e\n\u003cli\u003eRecovered baseline post-2024 shortages\u003c\/li\u003e\n\u003cli\u003eODT formulation boosts adherence and differentiation\u003c\/li\u003e\n\u003cli\u003eRequires ongoing promotion vs generics\/branded rivals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic CNS Sales Force Leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAytu’s specialized Central Nervous System sales force is a Star unit, driving rapid adoption of new and existing therapies across an expanding prescriber network and helping capture share in MDD and ADHD.\u003c\/p\u003e\n\u003cp\u003eThe team was a primary driver of a 32% total revenue surge in fiscal 2025, showing high productivity in a growing therapeutic segment while requiring heavy investment in training and compensation to sustain growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e32% revenue growth FY2025\u003c\/li\u003e\n\u003cli\u003eHigh prescriber adoption rates\u003c\/li\u003e\n\u003cli\u003eSignificant training \u0026amp; comp costs\u003c\/li\u003e\n\u003cli\u003eCritical for MDD and ADHD market share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEXXUA launch fuels $800M–$1.2B peak; Pediatric +77%, RxConnect cuts costs, CNS +32%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: EXXUA (launched Q4 2025) projected peak sales $800M–$1.2B by 2030; Pediatric portfolio 2025 sales ~$48M (+77% YoY); RxConnect drives 92% fulfillment, 28% lower OOP, saves ~$14 per script; CNS sales force drove 32% revenue growth FY2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEXXUA\u003c\/td\u003e\n\u003ctd\u003eLaunched Q4 2025\u003c\/td\u003e\n\u003ctd\u003ePeak $800M–$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePediatric\u003c\/td\u003e\n\u003ctd\u003e$48M\u003c\/td\u003e\n\u003ctd\u003e+77% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRxConnect\u003c\/td\u003e\n\u003ctd\u003e92% fill\u003c\/td\u003e\n\u003ctd\u003e-28% OOP; -$14\/script\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCNS sales\u003c\/td\u003e\n\u003ctd\u003eFY2025\u003c\/td\u003e\n\u003ctd\u003e+32% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Aytu’s portfolio with strategic actions for Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Aytu BCG Matrix placing each product in a quadrant for quick portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eADHD Portfolio Revenue Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe ADHD portfolio, led by Adzenys (amphetamine HFA) and Cotempla (methylphenidate XR), is Aytu’s primary Cash Cow, delivering 57.6 million dollars in net revenue for fiscal 2025 and funding new initiatives.\u003c\/p\u003e\n\u003cp\u003eDespite a mature, competitive ADHD market, these brands produce steady cash flow used to support the EXXUA launch and ongoing R\u0026amp;D spend.\u003c\/p\u003e\n\u003cp\u003eThe portfolio’s maturity allows Aytu to milk consistent adjusted EBITDA, which reached 9.2 million dollars for the full year 2025, underpinning capital allocation decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCotempla XR-ODT Market Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCotempla XR-ODT holds a solid niche in pediatric ADHD for long-acting methylphenidate in an orally disintegrating tablet, capturing about 12% of the pediatric methylphenidate ODT market in 2025 per IQVIA data.\u003c\/p\u003e\n\u003cp\u003eAs a mature brand with strong prescriber loyalty, promotional spend is ~35% lower than Aytu’s 2024 average for new launches, supporting higher gross margins near 68% in FY 2025.\u003c\/p\u003e\n\u003cp\u003eIts steady sales—roughly $28M in revenue in the trailing twelve months to Q3 2025—helped Aytu record seven consecutive quarters of positive adjusted EBITDA through Q3 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePoly-Vi-Flor and Tri-Vi-Flor Vitamin Lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePoly-Vi-Flor and Tri-Vi-Flor are Cash Cows in Aytu’s Pediatric portfolio, selling in a mature U.S. market with ~5–7% annual volume decline but stable unit margins near 40% as of FY2024.\u003c\/p\u003e\n\u003cp\u003eThey keep steady cash flow—estimated $8–10M annual EBITDA in 2024—thanks to pediatrician brand recognition and low marketing spend (\u0026lt;2% of sales).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Cost Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFollowing the 2024 closure of Aytu's Texas manufacturing facility and shift to contract manufacturing, the company cut fixed overhead by about $12–15 million annually, turning supply chain into a cash-generating asset by 2025.\u003c\/p\u003e\n\u003cp\u003eReduced cost of goods sold boosted gross margin on mature products from ~28% in 2023 to about 38% in 2025, freeing cash for R\u0026amp;D and commercial growth.\u003c\/p\u003e\n\u003cp\u003eOperational efficiencies now serve as a cash cow, funneling roughly $10–13 million in annual free cash flow into high-growth areas.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$12–15M overhead saved\u003c\/li\u003e\n\u003cli\u003eGross margin +10pts (28%→38%)\u003c\/li\u003e\n\u003cli\u003e$10–13M added free cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Payer and Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAytu’s established payer contracts and national distribution reach act as cash cows, delivering steady margins from mature products such as Adzenys; in 2025 these channels contributed roughly 60–65% of product revenue and stabilized cash flow.\u003c\/p\u003e\n\u003cp\u003eBy 2025 the company tightened gross-to-net leakage, boosting net realizations by ~4–6 percentage points versus 2022, so a larger share of each dollar from mature SKUs drops to operating profit.\u003c\/p\u003e\n\u003cp\u003eThis logistics and reimbursement backbone needs low incremental capex—estimated at under 5% of revenue annually—while underpinning overall liquidity and funding for growth programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 share: 60–65% revenue from mature products\u003c\/li\u003e\n\u003cli\u003eGross-to-net improvement: +4–6 pts vs 2022\u003c\/li\u003e\n\u003cli\u003eMaintenance capex: \u0026lt;5% of revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRestructuring lifts margins to ~38%, driving $10–13M FCF with $57.6M ADHD revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe ADHD duo (Adzenys, Cotempla) and Pediatric vitamins (Poly‑Vi‑Flor, Tri‑Vi‑Flor) generated stable cash: $57.6M net revenue and $9.2M adjusted EBITDA for ADHD in FY2025; vitamins ~ $8–10M EBITDA in 2024; cost cuts saved $12–15M, boosting gross margin ~+10 pts to ~38% by 2025 and adding $10–13M free cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (FY2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eADHD revenue\u003c\/td\u003e\n\u003ctd\u003e$57.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eADHD adj. EBITDA\u003c\/td\u003e\n\u003ctd\u003e$9.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVitamins EBITDA\u003c\/td\u003e\n\u003ctd\u003e$8–10M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverhead saved\u003c\/td\u003e\n\u003ctd\u003e$12–15M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (mature)\u003c\/td\u003e\n\u003ctd\u003e~38% (+10 pts)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree cash flow boost\u003c\/td\u003e\n\u003ctd\u003e$10–13M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eAytu BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact BCG Matrix report you'll receive after purchase—no watermarks, no demo text, just the fully formatted, analysis-ready document designed for strategic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748437340537,"sku":"aytubio-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/aytubio-bcg-matrix.png?v=1772208099","url":"https:\/\/growthsharematrix.com\/products\/aytubio-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}